Cadila Healthcare, along with subsidiary Zydus Pharmaceuticals (USA) Inc, has finalized an agreement with Supernus Pharmaceuticals Inc to settle all outstanding patent litigation related to Trokendi XR (topiramate) extended-release capsules.
Under the terms of the pact, Supernus grants a license to market Zydus' generic version of Trokendi XR (topiramate) extended-release capsules beginning on January 1, 2023, or earlier, under certain circumstances. The drug is used for treatment of certain types of seizures.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
